LLY · News · 20260826N

Competition and market share - oral GLP-1

ELI LILLY & Co · 2026-08-26 · Importance 17 · Surprise 24

Third-party reporting described the oral obesity-drug market as becoming increasingly competitive. Novo Nordisk and Eli Lilly were identified as the leading competitors in the emerging oral obesity segment. The competitive intensity could affect commercialization and market-share dynamics for Lilly’s oral GLP-1 programs, including Foundayo.

Key facts

• The news digest states the oral obesity market is heating up with fierce competition between Novo Nordisk and Eli Lilly. source